Online inquiry

IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5539MR)

This product GTTS-WQ5539MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD40LG gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000074.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 959
UniProt ID P29965
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5539MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10366MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY2062430
GTTS-WQ8430MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ2791MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG-282
GTTS-WQ13364MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ8870MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ1733MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ1130MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-927
GTTS-WQ9917MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA KB-003
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW